Modigraf (Tacrolimus)

Tacrolimus, the active ingredient in Modigraf, is a calcineurin inhibitor presented as an oral formulation for systemic use. It is employed to prevent organ transplant rejection by suppressing immune activation in adult patients who have received a kidney, liver, heart or other solid organ transplant.

GNH USA supplies Modigraf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, with distribution aligned to EU regulatory standards. The company ensures quality‑assured batches and supports global procurement.

Tacrolimus is a calcineurin inhibitor used in transplant immunology to prevent graft rejection.

- Kidney transplant: helps maintain graft function by reducing immune‑mediated rejection. - Liver transplant: lowers the risk of acute rejection episodes after surgery. - Heart transplant: supports long‑term graft survival by inhibiting T‑cell activation. - Lung transplant: assists in preventing chronic rejection and improves post‑operative outcomes.

Adverse reactions may occur with oral tacrolimus therapy and vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Tremor: fine shaking of hands or limbs. - Nausea: occasional upset stomach. - Diarrhea: loose stools. - Hypertension: elevated blood pressure readings. - Hyperglycemia: increased blood sugar levels.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function. - Neurotoxicity: seizures or severe confusion. - Infections: heightened susceptibility to bacterial, viral or fungal infections. - Malignancy: increased risk of certain cancers. - Hepatotoxicity: abnormal liver enzyme elevations.

Patients receiving Modigraf should be monitored closely for safety and efficacy.

- Monitor blood tacrolimus levels: adjust dose to maintain therapeutic range. - Assess renal function regularly: watch for signs of nephrotoxicity. - Check blood pressure: manage hypertension promptly. - Screen for infections: educate on signs and provide prophylaxis when needed. - Avoid concomitant nephrotoxic drugs: limit use of NSAIDs and certain antibiotics. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Tacrolimus interacts with several medicines that can alter its concentration or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause toxic levels. - Macrolide antibiotics (e.g., clarithromycin): increase tacrolimus exposure. - Ritonavir and other protease inhibitors: elevate drug concentrations.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., diltiazem): may raise tacrolimus levels. - Diuretics (e.g., furosemide): can enhance nephrotoxic risk. - Statins (e.g., simvastatin): increase risk of myopathy when combined.